Healio4d
Oral vancomycin may offer ‘viable option’ for IBD-related primary sclerosing cholangitis
Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...
Le Lézard5d
Estonia Strengthens Digital Collaboration with Saudi Arabia, Showcasing Innovation in ICT
Estonia strengthened its digital ties with the Kingdom of Saudi Arabia (KSA) as the Estonian business delegation, together with Minister of Justice and Digital Affairs Liisa-Ly Pakosta, visited the ...
‘I'm not normal anymore': Hair stylist sues companies over link between hair dye and cancer
The WHO’s cancer agency’s designation for hairstylists does not extend to people who dye their hair. That remains “not ...
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
Drugmakers Step Back From Diversity Pledges in Bow to Trump
Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so ...
Le Lézard10d
Aker Carbon Capture ASA proposes a cash dividend of NOK 3.5 billion
Estonia strengthened its digital ties with the Kingdom of Saudi Arabia (KSA) as the Estonian business ... visited the country during the LEAP 2025 technology conference.... Bristol Myers Squibb today ...
Business Insider15d
Bristol-Myers Squibb (BMY) Gets a Hold from Citi
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.
Nasdaq16d
BRISTOL-MYERS SQUIBB Earnings Results: $BMY Reports Quarterly Earnings
BRISTOL-MYERS SQUIBB ($BMY) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $1.67 per share, beating estimates of $1.47 ...
Insider Monkey16d
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years”
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks Jim Cramer discusses. In a recent appearance on CNBC’s Squawk on the ...
Benzinga.com16d
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...
FiercePharma16d
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
Just nine months after announcing a hefty plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money. The new plan, which has been dubbed a ...
NBC New York16d
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...